Crinetics Pharmaceuticals CRNX 深 滬
已收盤 09-26 16:00:00 美东时间
45.91
+10.020
+27.92%
華盛通- 最 高46.94
- 今 開41.07
- 成交量 1021.67万股
- 最 低 39.99
- 昨 收 35.89
- 總市值 43.24亿
- 52周最高 62.53
- 市盈率 靜 --
- 換手率 10.85%
- 52周最低 24.10
- 委 比 18.68%
- 總股本 9417.60万
- 歷史最高 62.53
- 量 比 5.40
- 振 幅 19.36%
- 歷史最低 10.63
- 每 手 1
- 風險率 10.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder
On Thursday, the U.S.
今天 01:07
Crinetics飙升26.6%，其肢端肥大症治疗药物获FDA批准
制药企业Crinetics Pharmaceuticals(CRNX)早盘飙升26.6%，获得美国FDA对肢端肥大症治疗药物Palsonify的批准。批准基于成...
09-26 22:57
Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts
Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
09-26 22:00
美股异动 | Crinetics(CRNX.US)盘初暴涨23% FDA批准其生长激素紊乱治疗方案
周五，Crinetics(CRNX.US)盘初暴涨23%，创8个月新高，报44.30美元。
09-26 21:57
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
09-26 20:10
Crinetics wins FDA approval for acromegaly therapy
Crinetics Pharmaceuticals (NASDAQ:CRNX) has received approval for its lead asset, Palsonify (paltusotine), as a first-line treatment for adults with acromegaly, a rare condition characterized by uneve...
09-26 18:53
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
The FDA has approved Palsonify as the first once-daily, oral therapy for acromegaly. It is a somatostatin receptor type 2 agonist shown to effectively control IGF-1 levels and reduce symptoms based on Phase 3 trials. Palsonify was generally well-tolerated, with no serious adverse events reported in controlled trials. It is now available in the U.S. and under review for approval in the European Union and Japan.
09-25 21:30
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
JP Morgan Maintains Overweight on Crinetics Pharmaceuticals, Lowers Price Target to $52
JP Morgan analyst Jessica Fye maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and lowers the price target from $53 to $52.
09-24 20:36
